Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 68071-3948

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 68071-3948). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3948 3)

NuCare Pharmaceuticals, Inc. offers Atorvastatin Calcium 40mg tablets in a package containing 30 film-coated tablets. The oval-shaped, white tablets are debossed with "LS" on one side and "249" on the other side. Each tablet contains Atorvastatin Calcium, USP equivalent to 40mg Atorvastatin. The lot number for this product is 00000 with an expiration date of 00-00. Customers are advised to call their doctor for medical advice and report any side effects to the FDA. It is important to keep this medication out of reach of children and store it at a controlled temperature of 68-77°F.*

FDA Label Image

Structural Formula (96f45871 7175 49d8 8374 Dfa2978d38c7 01)

FDA Label Image

Figure1 (96f45871 7175 49d8 8374 Dfa2978d38c7 02)

This text appears to show cumulative incidence percentages alongside hazard ratio (HR) and p-value for a certain study or analysis. The cumulative incidence percentages range from 0.8% to 30%. The hazard ratio is noted as 0.64 with a confidence interval of 0.50 to 0.83, and a p-value of 0.0005. The duration mentioned in the text is 3.5 years.*

FDA Label Image

Figure2 (96f45871 7175 49d8 8374 Dfa2978d38c7 03)

This text indicates information related to a clinical study involving Atorvastatin. It presents a hazard ratio of 0.63 with a confidence interval of 0.48-0.83 and a p-value of 0.001. The study likely investigated the time to the first primary endpoint over a four-year follow-up period. This suggests that Atorvastatin may have a significant impact on reducing this primary endpoint within the specified time frame.*

FDA Label Image

Figure3 (96f45871 7175 49d8 8374 Dfa2978d38c7 04)

This text provides data on the percentage of subjects experiencing an event while taking Atorvastatin at different dosages (10mg and 80mg). It also shows the Hazard Ratio (HR) and the significance level (P-value) for the observed outcome. Additionally, it mentions the time to the first major cardiovascular endpoint in years.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.